These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23679904)

  • 1. Clinical and microbiological efficacy of tigecycline for complicated skin-soft-tissue and intra-abdominal infections in a Turkish university hospital.
    Avkan-Oguz V; Yapar N; Alp-Cavus S; Demir Onder K; Aktas E; Gulay Z; Cakır N
    Int J Clin Pract; 2013 Jun; 67(6):505-11. PubMed ID: 23679904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies.
    Heizmann WR; Dupont H; Montravers P; Guirao X; Eckmann C; Bassetti M; García MS; Capparella MR; Simoneau D; Bodmann KF
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii45-55. PubMed ID: 23772046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies.
    Guirao X; Sánchez García M; Bassetti M; Bodmann KF; Dupont H; Montravers P; Heizmann WR; Capparella MR; Simoneau D; Eckmann C
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii37-44. PubMed ID: 23772045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.
    Bassetti M; McGovern PC; Wenisch C; Meyer RD; Yan JL; Wible M; Rottinghaus ST; Quintana A
    Int J Antimicrob Agents; 2015 Sep; 46(3):346-50. PubMed ID: 26155003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
    Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies.
    Montravers P; Bassetti M; Dupont H; Eckmann C; Heizmann WR; Guirao X; García MS; Capparella MR; Simoneau D; Bodmann KF
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii15-24. PubMed ID: 23772042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.
    Bodmann KF; Heizmann WR; von Eiff C; Petrik C; Löschmann PA; Eckmann C
    Chemotherapy; 2012; 58(4):282-94. PubMed ID: 23052187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of age on the clinical efficacy of tigecycline in severely ill patients.
    Bassetti M; Guirao X; Montravers P; Rossolini GM; Sánchez García M; Sganga G; Eckmann C
    J Glob Antimicrob Resist; 2019 Sep; 18():199-206. PubMed ID: 30953830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies.
    Eckmann C; Montravers P; Bassetti M; Bodmann KF; Heizmann WR; Sánchez García M; Guirao X; Capparella MR; Simoneau D; Dupont H
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii25-35. PubMed ID: 23772043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is tigecycline drug of choice for cIAI and cSSTI?
    Hosgor-Limoncu M
    Int J Clin Pract; 2013 Jun; 67(6):492-3. PubMed ID: 23679901
    [No Abstract]   [Full Text] [Related]  

  • 11. Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice.
    Eckmann C; Heizmann WR; Leitner E; von Eiff C; Bodmann KF
    Chemotherapy; 2011; 57(4):275-84. PubMed ID: 21778715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tigecycline: an antibiotic for the twenty-first century.
    Dryden M
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii3-4. PubMed ID: 23772044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.
    Grolman DC
    Int J Infect Dis; 2007 May; 11 Suppl 1():S7-15. PubMed ID: 17603950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infections.
    Wilcox MH
    J Chemother; 2005 Aug; 17 Suppl 1():23-9. PubMed ID: 16285355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tigecycline in the Treatment of Patients with Necrotizing Skin and Soft Tissue Infections Due to Multiresistant Bacteria.
    Eckmann C; Heizmann W; Bodmann KF; von Eiff C; Petrik C; Loeschmann PA
    Surg Infect (Larchmt); 2015 Oct; 16(5):618-25. PubMed ID: 26115414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tigecycline: an update.
    Stein GE; Babinchak T
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing the role of tigecycline in an era of antimicrobial resistance.
    Schafer JJ; Goff DA
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tigecycline: a glycylcycline antimicrobial agent.
    Doan TL; Fung HB; Mehta D; Riska PF
    Clin Ther; 2006 Aug; 28(8):1079-1106. PubMed ID: 16982286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
    Bradford PA; Weaver-Sands DT; Petersen PJ
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S315-32. PubMed ID: 16080070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.